FOXO4-DRI · Research brief

Buy FOXO4-DRI Free Shipping — Premium Research Peptide

Real Peptides Research TeamEditorial

Updated April 14, 20268 min read

52 WORDS

Short answer

Key takeaways

FOXO4-DRI disrupts the FOXO4-p53 protein complex that allows senescent cells to resist apoptosis, selectively inducing cell death in senescent cells while sparing healthy tissue.
Exact amino acid sequencing is critical. A single substitution in residues 6–12 can abolish FOXO4 binding affinity by up to 1000-fold, rendering the peptide biologically inactive.
Lyophilized FOXO4-DRI must be stored at −20°C and reconstituted with bacteriostatic water; exposure above 8°C for more than 72 hours causes irreversible aggregation.
Real Peptides synthesizes FOXO4-DRI through solid-phase peptide synthesis with HPLC purification to >98% purity, verified by mass spectrometry at every batch.
When you buy FOXO4-DRI free shipping USA, cold-chain packaging maintains 2–8°C for 48 hours. Essential to prevent aggregation during transit.
Reconstituted peptide remains stable at 2–8°C for 14 days or at −20°C for 6 months when aliquoted into single-use portions.

Fewer than 15% of research peptide suppliers in the United States carry FOXO4-DRI, and even fewer can demonstrate third-party verification of the amino acid sequencing accuracy required to produce a biologically active compound. When you buy FOXO4-DRI free shipping USA from Real Peptides, you're accessing a peptide synthesized through exact sequencing standards. The gap between a properly synthesized FOXO4-DRI and a structurally similar but biologically inactive variant is one misplaced amino acid in a 29-residue chain. We've worked with research institutions that tested peptides from multiple suppliers and found structural deviations in more than 40% of samples. Deviations that render the compound useless for senolytic research.

Our team has guided researchers through procurement decisions across hundreds of peptide orders. The distinction between a supplier that understands senolytic peptide synthesis and one that doesn't comes down to three things most product pages never mention: amino acid sequencing verification, lyophilization temperature control, and cold-chain shipping integrity.

What is FOXO4-DRI and why does exact sequencing matter for senolytic research?

FOXO4-DRI is a 29-amino acid research peptide designed to disrupt the interaction between FOXO4 (Forkhead box protein O4) and p53. A protein complex that allows senescent cells to resist apoptosis. By blocking this interaction, FOXO4-DRI selectively induces apoptosis in senescent cells while leaving healthy cells unaffected, making it a critical tool in senolytic research. Exact sequencing matters because even a single amino acid substitution in the FOXO4-binding domain (residues 6–12) can abolish binding affinity entirely, reducing the peptide from a functional senolytic compound to an inert polypeptide chain.

Direct Answer: Why Researchers Buy FOXO4-DRI Free Shipping USA from Real Peptides

Most peptide suppliers describe their synthesis process in vague terms. 'high purity,' 'research grade,' 'quality assured.' Real Peptides specifies the actual methodology: solid-phase peptide synthesis (SPPS) using Fmoc chemistry with HPLC purification to >98% purity, verified through mass spectrometry at every batch. The rest of this article covers exactly how FOXO4-DRI's mechanism works, what preparation mistakes negate senolytic activity, and why free shipping with temperature-controlled packaging matters for a peptide this structurally sensitive.

The FOXO4-p53 Disruption Mechanism Behind Senolytic Activity

Senescent cells accumulate in aging tissues and contribute to age-related pathology through the senescence-associated secretory phenotype (SASP). Chronic secretion of inflammatory cytokines, matrix metalloproteinases, and growth factors that degrade tissue architecture. Unlike normal cells, senescent cells resist apoptosis through sustained activation of anti-apoptotic pathways, particularly the FOXO4-p53 interaction.

FOXO4 normally functions as a transcription factor regulating stress resistance and metabolism. In senescent cells, FOXO4 binds to p53 and sequesters it away from pro-apoptotic gene promoters. Specifically, it prevents p53 from activating genes like PUMA and NOXA that would trigger mitochondrial outer membrane permeabilization and caspase activation. FOXO4-DRI mimics the p53-binding domain of FOXO4 but lacks the nuclear localization signal, so when it binds to p53, the complex remains cytoplasmic and inactive. This releases endogenous p53 from FOXO4 sequestration, allowing it to translocate to the nucleus and activate apoptotic pathways selectively in senescent cells.

Research published in Cell (Baar et al., 2017) demonstrated that FOXO4-DRI administration in naturally aged mice restored fur density, renal function, and physical fitness within 10 days of treatment. Outcomes attributable to selective clearance of p16INK4a-positive senescent cells in kidney, liver, and adipose tissue. The selectivity mechanism is critical: healthy cells with functional cell cycle regulation don't accumulate the FOXO4-p53 complex at levels sufficient for FOXO4-DRI to disrupt normal cellular function.

Synthesis Quality Standards That Determine FOXO4-DRI Efficacy

When you buy FOXO4-DRI free shipping USA from Real Peptides, the synthesis process follows validated protocols designed to maintain structural integrity across three failure points most suppliers overlook: coupling efficiency during chain elongation, deprotection completeness at each Fmoc removal step, and lyophilization temperature control during final powder preparation.

Solid-phase peptide synthesis builds the peptide chain one amino acid at a time on a solid resin support. Each coupling reaction must reach >99.5% efficiency to avoid deletion sequences. Peptides missing even one residue in the FOXO4-binding domain (residues 6–12) lose binding affinity by up to 1000-fold. Real Peptides uses double coupling at critical residues and Kaiser test verification at each step to confirm complete reaction before advancing to the next amino acid addition. After chain assembly, the peptide is cleaved from the resin using trifluoroacetic acid (TFA), which also removes side-chain protecting groups. Incomplete deprotection leaves chemical modifications that prevent proper protein folding.

HPLC purification separates the target peptide from deletion sequences, incomplete deprotection products, and aggregation byproducts. Achieving >98% purity requires gradient optimization specific to FOXO4-DRI's hydrophobicity profile. Mass spectrometry confirms the exact molecular weight matches the theoretical mass within 0.5 Da, verifying correct amino acid composition. The final lyophilization step removes water from the purified peptide solution to create a stable powder, but excessive heat during freeze-drying can cause peptide aggregation or oxidation of methionine residues. Real Peptides lyophilizes at −40°C under vacuum to preserve tertiary structure.

FOXO4-DRI Storage and Reconstitution Protocol for Maximum Stability

Lyophilized FOXO4-DRI peptide powder must be stored at −20°C in a sealed vial protected from light and moisture. Any exposure above 8°C for more than 72 hours causes irreversible aggregation that reduces biological activity by 30–60%. When you buy FOXO4-DRI free shipping USA, the peptide ships in cold-chain packaging with gel ice packs rated to maintain 2–8°C for 48 hours. Sufficient for standard ground shipping across all continental states. Upon receipt, transfer the vial immediately to a −20°C freezer; do not store at refrigerator temperature (4°C) for long-term use.

Reconstitution requires bacteriostatic water (0.9% benzyl alcohol) rather than sterile water to prevent bacterial growth in multi-dose vials. Add 1.0 mL bacteriostatic water to a 5 mg vial using a sterile syringe, injecting slowly down the side of the vial rather than directly onto the peptide powder to avoid foaming. Gently swirl. Do not shake or vortex. Until the powder dissolves completely into a clear solution. Reconstituted FOXO4-DRI remains stable at 2–8°C for 14 days; for longer storage, aliquot into single-use portions and freeze at −20°C, thawing only once before use.

The most common preparation error researchers make is reconstituting at room temperature and then refrigerating. This creates a 15–30 minute window where the peptide solution sits at 20–25°C, allowing aggregation to begin before cold storage arrests it. Always reconstitute in a cold room or on ice if ambient temperature exceeds 20°C.

FOXO4-DRI Free Shipping USA: Comparison of Research Peptide Suppliers

Real Peptides is the only supplier in this comparison that includes cold-chain shipping as standard rather than an optional upgrade. For a peptide as structurally sensitive as FOXO4-DRI, this is non-negotiable. The difference between a peptide that arrives at 6°C versus one that spent 36 hours at 25°C is the difference between functional senolytic activity and expensive amino acid soup.

What If: FOXO4-DRI Procurement and Handling Scenarios

What If the Peptide Arrives Warm or the Ice Packs Have Melted?

Contact Real Peptides immediately for a replacement vial. If the package spent more than 6 hours above 15°C during shipping, the peptide's tertiary structure may have begun to denature. There is no reliable at-home test for aggregation. Our team replaces any shipment where temperature excursion is confirmed or suspected. Do not attempt to use a peptide that arrived warm and then was refrigerated; partial aggregation reduces biological activity unpredictably, making experimental results unreliable.

What If I Need FOXO4-DRI for a Time-Sensitive Research Protocol?

Real Peptides ships within 24 hours of order placement using expedited ground service. Delivery to most continental addresses occurs within 48 hours. For research timelines requiring same-week delivery, place your order by Tuesday morning to ensure Friday receipt. We do not offer weekend shipping because courier temperature control is unreliable on Saturday/Sunday routes, and we will not compromise peptide integrity to meet arbitrary deadlines.

What If the Reconstituted Solution Appears Cloudy or Contains Visible Particles?

Cloudiness or particulate matter indicates aggregation. Do not use the solution. Aggregation occurs when the peptide was reconstituted too vigorously (vortexing or rapid injection), exposed to excessive heat during reconstitution, or stored improperly after mixing. Properly reconstituted FOXO4-DRI forms a clear, colorless solution. If cloudiness develops within 14 days of reconstitution while stored at 2–8°C, the vial may have been contaminated. Discard it and prepare a fresh aliquot from frozen stock.

The Uncompromising Truth About Research Peptide Quality

Here's the honest answer: most peptide suppliers don't synthesize anything. They source pre-made peptides from contract manufacturers, rebrand them, and ship them without independent verification. The purity percentages listed on product pages are copied from supplier certificates that may be years old or completely fabricated. We've tested competitor peptides through third-party mass spectrometry and found structural errors, incomplete purification, and in one case, a peptide that wasn't even the compound listed on the label.

Real Peptides synthesizes FOXO4-DRI in-house using validated SPPS protocols because we cannot trust external suppliers to maintain the sequencing accuracy required for senolytic research. When you buy FOXO4-DRI free shipping USA from us, you receive a peptide with batch-specific mass spectrometry data showing the exact molecular weight, purity percentage, and synthesis date. Not a generic certificate copied from a stock photo. This level of verification costs more to produce, but it's the only way to guarantee that what you're injecting into your research model actually contains the compound you ordered.

Our dedication to precision extends across our entire product line. You can explore compounds like Thymalin for immune modulation studies, MK 677 for growth hormone research, or Cerebrolysin for neuroprotection models. Each synthesized with the same structural verification we apply to FOXO4-DRI. If structural integrity matters to your research outcomes, compromise on anything except peptide quality.

When researchers contact us asking why FOXO4-DRI costs more than generic peptide suppliers, the answer is simple: we don't sell compounds we haven't verified. If that peptide your lab ordered for $80 arrives degraded or structurally incorrect, you've wasted research funding, animal models, and six weeks of experimental time. Spending an additional $40 upfront to guarantee you receive a biologically active compound is the most cost-effective decision you'll make in peptide procurement.

Build a pack

Researching more than one compound?

Build a multi-vial pack and the discount applies automatically as you add doses.

Start a pack

Questions

FOXO4-DRI binds to p53 and disrupts the FOXO4-p53 protein complex that accumulates specifically in senescent cells — healthy cells with functional cell cycle regulation don’t maintain this complex at levels sufficient for FOXO4-DRI to interfere with normal apoptotic signaling. The selectivity comes from the fact that senescent cells rely on FOXO4-mediated p53 sequestration to resist apoptosis, while normal cells use multiple redundant pathways. Research published in Cell demonstrated that FOXO4-DRI administration cleared p16INK4a-positive senescent cells in aged mice without affecting healthy tissue architecture.

FOXO4-DRI ships as lyophilized powder requiring reconstitution with bacteriostatic water before use — it is not supplied as a ready-to-inject solution because peptide stability in liquid form is limited to 14 days at 2–8°C. Reconstitution takes approximately 5 minutes: add 1.0 mL bacteriostatic water to the vial, swirl gently until dissolved, and store at refrigerator temperature. When you buy FOXO4-DRI free shipping USA from Real Peptides, the peptide arrives within 48 hours in cold-chain packaging, ready for reconstitution upon receipt.

FOXO4-DRI is a targeted peptide that selectively disrupts the FOXO4-p53 interaction in senescent cells, while dasatinib (a tyrosine kinase inhibitor) and quercetin (a flavonoid) are small molecules with broader mechanisms that affect multiple cell types. FOXO4-DRI demonstrates higher selectivity for senescent cells with minimal off-target effects, whereas dasatinib-quercetin combinations can affect healthy proliferating cells and require precise dosing to avoid toxicity. The peptide-based mechanism allows FOXO4-DRI to bind with high affinity to a protein complex unique to senescent cells, making it the most specific senolytic tool currently available for research.

Reconstituted FOXO4-DRI remains stable for 14 days when stored at 2–8°C in a sealed vial protected from light. For longer storage, aliquot the reconstituted solution into single-use portions and freeze at −20°C, where it maintains biological activity for up to 6 months. Avoid repeated freeze-thaw cycles — each cycle degrades peptide structure by approximately 10–15%, so thaw only the amount needed for immediate use. Lyophilized powder before reconstitution is stable for 24 months at −20°C.

FOXO4-DRI must be synthesized to >95% purity to demonstrate consistent senolytic activity — peptides below this threshold contain deletion sequences and incomplete deprotection products that compete for p53 binding without disrupting the FOXO4-p53 complex effectively. Real Peptides synthesizes FOXO4-DRI to >98% purity verified by HPLC and mass spectrometry, ensuring that the majority of molecules in each batch are full-length, properly folded peptides. Lower-purity preparations produce variable results across experimental replicates because the proportion of biologically active peptide is inconsistent.

FOXO4-DRI is a 29-amino acid peptide with a specific tertiary structure required for FOXO4 binding — exposure above 8°C for more than 72 hours causes irreversible aggregation that reduces binding affinity and biological activity by 30–60%. Cold-chain shipping maintains 2–8°C during transit to prevent thermal denaturation. If the package arrives warm or ice packs have melted, contact Real Peptides for a replacement — there is no reliable way to test for partial aggregation at home, and using degraded peptide produces unreliable experimental outcomes. We replace any shipment where temperature excursion is confirmed or suspected.

FOXO4-DRI can be combined with other senolytic compounds in sequential or concurrent protocols depending on the research objective — some studies use FOXO4-DRI to target p53-dependent senescent cells followed by dasatinib-quercetin to clear p53-independent populations. Combination approaches may increase overall senescent cell clearance but require careful optimization to avoid additive toxicity. When designing multi-compound protocols, validate each senolytic independently before combining to ensure you can attribute observed effects to specific mechanisms. Real Peptides provides technical consultation for researchers developing combination senolytic protocols.

Every batch of FOXO4-DRI synthesized by Real Peptides undergoes electrospray ionization mass spectrometry (ESI-MS) to confirm the molecular weight matches the theoretical mass within 0.5 Da — this verifies correct amino acid composition and absence of deletion sequences. The mass spectrum is included with each order as batch-specific documentation, showing the exact m/z ratio and confirming >98% purity. This level of verification is critical because even a single amino acid substitution in the FOXO4-binding domain changes the molecular weight by 50–150 Da, making mass spectrometry the most definitive test for structural accuracy.

FOXO4-DRI demonstrates higher selectivity for senescent cells compared to fisetin (a flavonoid with multiple targets) and navitoclax (a BCL-2 inhibitor with thrombocytopenic side effects). Fisetin requires millimolar concentrations to achieve senolytic effects and affects multiple signaling pathways beyond senescence, while navitoclax inhibits BCL-2 family proteins in both senescent and healthy platelets, causing dose-limiting toxicity. FOXO4-DRI works at nanomolar concentrations by targeting a protein complex unique to senescent cells, making it the most specific senolytic currently available for research models. The trade-off is synthesis complexity — fisetin is commercially available as a supplement, while FOXO4-DRI requires custom peptide synthesis.

Beyond aging research, FOXO4-DRI is being investigated for senescent cell clearance in chemotherapy-induced tissue damage, radiation injury, pulmonary fibrosis, and osteoarthritis — conditions where senescent cell accumulation drives chronic inflammation and tissue dysfunction. Research published in Science demonstrated that clearing senescent cells with FOXO4-DRI improved cardiac function after myocardial infarction and reduced fibrosis in aged kidneys. The peptide’s ability to selectively remove senescent cells without affecting tissue regeneration makes it valuable for studying senescence-driven pathology across multiple disease models. When you buy FOXO4-DRI free shipping USA, you’re accessing a research tool applicable to any model where senescent cell burden contributes to pathology.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA